Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2

Biological & Pharmaceutical Bulletin
Hiroki OhyaKen Iseki

Abstract

Regorafenib is a small molecule inhibitor of tyrosine kinases, and has been shown to improve the outcomes of patients with advanced colorectal cancer and advanced gastrointestinal stromal tumors. The transport profiles of regorafenib by various transporters were evaluated. HEK293/organic anion transporting polypeptide 1B1 (OATP1B1) cells exhibited increased drug sensitivity to regorafenib. Regorafenib inhibited the uptake of 3H-estrone sulfate by HEK293/OATP1B1 cells in a dose-dependent manner, but did not affect its elimination by P-glycoproteins. The concentration of regorafenib was significantly lower in LLC-PK1/multidrug resistance protein 2 (MRP2) cells than in LLC-PK1 cells treated with the MRP2 inhibitor, MK571. MK571 abolished the inhibitory effects of regorafenib on intracellular accumulation in LLC-PK1/MRP2 cells. The uptake of regorafenib was significantly higher in HEK293/OATP1B1 cells than in OATP1B1-mock cells. Transport kinetics values were estimated to be Km=15.9 µM and Vmax=1.24 nmol/mg/min. No significant difference was observed in regorafenib concentrations between HEK293/OATP1B3 and OATP1B3-mock cells. These results indicated that regorafenib is a substrate for MRP2 and OATP1B1, and also suggest that the sub...Continue Reading

References

Jul 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Phillip M Gerk, Mary Vore
Jun 26, 2003·Cancer Science·Motoi MukaiShin-Ichi Akiyama
Nov 25, 2003·Gut·C G DietrichR P J Oude Elferink
Apr 22, 2006·The Journal of Pharmacology and Experimental Therapeutics·Lichuan LiuK Sandy Pang
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shuiying HuAlex Sparreboom
Mar 5, 2011·Biological & Pharmaceutical Bulletin·Hiroaki YamaguchiNariyasu Mano
Mar 5, 2011·Biological & Pharmaceutical Bulletin·Yoshihiko ShibayamaKatsushi Yamada
Aug 23, 2011·Annual Review of Pharmacology and Toxicology·Amanda ObaidatBruno Hagenbuch
Jan 13, 2012·Chinese Journal of Cancer·Miao He, Min-Jie Wei
Sep 10, 2013·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Nielka P van ErpJan den Hartigh
Sep 18, 2013·Critical Reviews in Oncology/hematology·Audrey Thomas-SchoemannFrançois Goldwasser
Jan 9, 2014·British Journal of Cancer·S HuA Sparreboom
Mar 20, 2014·Drug Metabolism and Drug Interactions·Varun KhuranaAshim K Mitra
May 9, 2014·Drug Metabolism and Drug Interactions·Varun KhuranaAshim K Mitra

❮ Previous
Next ❯

Citations

Oct 25, 2016·Trends in Pharmacological Sciences·Claudia NeulAnne T Nies
Oct 17, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Hiroyoshi KoideKohshi Nishiguchi
Oct 29, 2018·Cancer Chemotherapy and Pharmacology·Akimitsu MaedaShoji Fukushima
Dec 24, 2018·The Journal of Pharmacology and Experimental Therapeutics·Dong Gui HuRobyn Meech
Feb 13, 2019·Expert Review of Clinical Pharmacology·Ruba Al-AbdullaJose J G Marin
Sep 13, 2020·Pharmaceutics·Dominique A GarrisonSharyn D Baker
Aug 16, 2019·World Journal of Gastroenterology : WJG·Elena De MattiaGiuseppe Toffoli
Jun 27, 2020·Cancers·Jose J G MarinOscar Briz
Sep 21, 2021·Seminars in Liver Disease·Jose J G MarinOscar Briz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.